PubMed
Gonadotropin-releasing hormone agonists and antagonists in assisted reproduction
Al-Inany HG, Youssef MA, Aboulghar M, et al. Cochrane Database Syst Rev. 2016
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 48% · Mixed 44% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 10–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 40% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 164 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 64% · Mixed 18% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 18 days · Based on 319 repeat reporters
Published sources linked on the Gonadorelin and Melanotan II wiki pages.
PubMed
Al-Inany HG, Youssef MA, Aboulghar M, et al. Cochrane Database Syst Rev. 2016
PubMed
Collado-Sole A, Borjini N, Zhai J, et al. Science (New York, N.Y.). 2026
PubMed
Moore AM. eLife. 2024
PubMed
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
PubMed
Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021
PubMed
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012